Docetaxel for injection (Albumin-bound)
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions
Adenocarcinoma of Gastroesophageal JunctionAdvanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid TumorsAdvanced Solid TumorsGastric AdenocarcinomaGastric CancerLocally Advanced Unresectable Esophageal Squamous CarcinomaPancreatic CancerPlatinum-resistant Recurrent Ovarian Cancer
Phase 1
The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere
NCT04811118
Start: 2021-05-18End: 2022-12-31Updated: 2022-01-31
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
Not yet recruitingNCT06136988
Start: 2023-12-31End: 2028-04-30Target: 129Updated: 2023-11-18
Phase 2
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
NCT05325229
Start: 2022-08-18End: 2024-12-31Target: 94Updated: 2022-10-13
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer
NCT05616494
Start: 2022-12-06End: 2025-06-30Target: 53Updated: 2023-03-22
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
NCT05705635
Start: 2023-01-13End: 2024-12-31Target: 100Updated: 2023-01-31
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors
RecruitingNCT06947291
Start: 2025-06-04End: 2027-10-30Target: 350Updated: 2025-09-08